Medications for OUD more likely for those with severe versus mild past-year OUD, receiving substance use treatment via telehealth
Significant improvement seen in 17-item Hamilton Depression Rating Scale, Clinical Global Impressions severity score
Improvement seen in measures of sleepiness, cataplexy over eight weeks versus placebo, but drug was associated with hepatotoxic effects
Pfizer is working to repair the damage and mitigate any shortage of drugs made at the facility
Four-week course efficacious and safe for treatment-resistant depression
Mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab, placebo
Implementation of training session increased proportion of patients with documented Abnormal Involuntary Movement Score
Slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population
Three case reports from Iceland spurred the review; two of the cases involved Ozempic
No evidence seen for link between childhood stimulant treatment and substance use during adolescence and young adulthood